Skip to content
L’Oréal takes 7.13% stake in Shenzhen biotech Pam²L

L’Oréal China (欧莱雅中国) has acquired a 7.13% stake in Shenzhen-based biotechnology startup Pam²L Biotechnologies (柏垠生物) through its investment arm Meicifang (美次方), for an undisclosed sum. Founded in 2021, Pam²L specializes in synthetic biology and recombinant proteins, including mussel adhesive proteins used in skincare and medical applications. The company has raised more than 300 million RMB ($45 million) to date and was selected for L’Oréal’s Big Bang beauty tech innovation program in 2024. The deal deepens L’Oréal’s focus on Chinese beauty technology, complementing its stakes in local brands. Since establishing Meicifang in 2022, the group has backed companies including Chando (自然堂) parent Jala Group (伽蓝集团) and skincare brand Lan (兰).

Related reading: L’Oréal takes longevity science to hair care

Luxury’s personalized toolkit for business in China. Join now to sharpen your focus.

Subscribe now

Have an account? Login